Alexion's Soliris wins $1B myasthenia gravis approval with broader-than-expected label
admin 24th October 2017 Uncategorised 0It took longer than some industry watchers expected, but Alexion has another indication for lead medication Soliris in the bag. On Monday, the company said the FDA had greenlighted the product to treat refractory generalized myasthenia gravis patients who are antiacetylcholine receptor antibody positive—a subset broader than the population treated in Alexion’s trial.
More: Alexion's Soliris wins B myasthenia gravis approval with broader-than-expected label
Source: fierce